CLOTRIMADERM VAGINAL 6 CREAM

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

CLOTRIMAZOLE

Disponible desde:

TARO PHARMACEUTICALS INC

Código ATC:

G01AF02

Designación común internacional (DCI):

CLOTRIMAZOLE

Dosis:

1%

formulario farmacéutico:

CREAM

Composición:

CLOTRIMAZOLE 1%

Vía de administración:

VAGINAL

Unidades en paquete:

50GM

tipo de receta:

OTC

Área terapéutica:

AZOLES

Resumen del producto:

Active ingredient group (AIG) number: 0110231001; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2020-02-21

Ficha técnica

_PAGE 1 OF 22_
_ _
_CLOTRIMADERM VAGINAL 6 _
_CLOTRIMADERM VAGINAL 3 _
_CLOTRIMADERM EXTERNAL CREAM _
PRODUCT
MO
N
OG
RA
PH
CLOTRIMADERM VAGINAL 6
(Clotrimazo le
Vaginal Cream USP 1%)
CLOTRIMADERM VAGINAL 3
(Clotrimazo le
Vaginal Cream USP 2%)
CLOTRIMADERM EXTERNAL C
RE
AM
(Clotrimazole
Vaginal Cream USP 1%)
ANTIFUNGAL
AG
E
NT
Taro Pharmaceuticals
Inc. Date of Revision:
130 East Drive
April 29, 2022
Brampton,
Ontario
L6T 1C1
CONTROL #263252
_PAGE 2 OF 22_
_ _
_CLOTRIMADERM VAGINAL 6 _
_CLOTRIMADERM VAGINAL 3 _
_CLOTRIMADERM EXTERNAL CREAM _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
3
WARNINGS AND
PRECAUTIONS.............................................................................................
3
ADVERSE REACTIONS
.............................................................................................................
4
DRUG INTERACTIONS
..............................................................................................................
5
DOSAGE AND
ADMINISTRATION...........................................................................................
6
OVERDOSAGE
............................................................................................................................
6
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
6
STORAGE AND
STABILITY.......................................................................................................
8
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................................. 8
PART II: SCIENTIFIC INFORMATION
....